Product
Elotuzumab
Aliases
BMS-901608, Elotuzumab (BMS-901608; HuLuc63), Elotuzumab in combination with lenalidomide and dexamethasone, Elotuzumab in combination with pomalidomide and dexamethasone (2 other aliases)
Name
Elotuzumab
INN Name
elotuzumab
Target
SLAMF-7
FDA Approved
Yes
Ema approved
Status
0
15 clinical trials
1 organization
1 abstract
7 indications
1 document
Indication
Multiple MyelomaIndication
Relapsed Refractory Multiple MyelomaIndication
Acute Myeloid LeukemiaIndication
acute myeloid leukemiaIndication
AdultIndication
IgG4-related diseaseIndication
Multiple Myeloma in RelapseClinical trial
A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMMStatus: Not yet recruiting, Estimated PCD: 2025-11-16
Clinical trial
An Expanded Access Program for Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma in JapanStatus:
Clinical trial
A Phase 3, Multicenter, Randomized, Open Label Study of ABBV-383 Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)Status: Not yet recruiting, Estimated PCD: 2027-12-06
Clinical trial
Empliciti® (Elotuzumab) Post-Marketing Surveillance Study for Patients With Multiple Myeloma in TaiwanStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)Status: Recruiting, Estimated PCD: 2032-12-26
Clinical trial
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating ElotuzumabStatus: Active (not recruiting), Estimated PCD: 2024-06-28
Clinical trial
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2027-04-01
Clinical trial
An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2022-03-09
Clinical trial
An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)Status: Completed, Estimated PCD: 2018-01-17
Clinical trial
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple MyelomaStatus: Completed, Estimated PCD: 2019-10-01
Clinical trial
An Expanded Access Program for Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaStatus:
Clinical trial
A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory Multiple MyelomaStatus: Terminated, Estimated PCD: 2023-07-13
Abstract
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study.Org: Schleswig-Holstein University Hospital, Hospital Salzburg Paracelus University, University Hospital rechts der Isar, Jena University Hospital, Wuerzburg University Medical Center,
Clinical trial
Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)Status: Terminated, Estimated PCD: 2024-01-04
Clinical trial
Phase 2 Study of Carfilzomib + Elotuzumab + Dexamethasone for Relapsed or Progressed Multiple Myeloma After 1-3 Prior Treatment LinesStatus: Completed, Estimated PCD: 2023-08-31
Clinical trial
A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) and Anti-TIGIT (BMS-986207)Status: Active (not recruiting), Estimated PCD: 2023-12-30
Document
DailyMed Label: EMPLICITIOrganization
E.R. Squibb & Sons, L.L.C.